Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases. | Roche is paying oncology-focused ...
About a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot, laying off most of its employees and seeking new homes for its assets. ArsenalBio is turning to ...
Medtronic is recalling certain esophageal pH monitoring capsule delivery devices amid the risk of them failing whilst ...
Novocure has become the latest medtech company to be hit by a cyberattack, with the oncology specialist revealing that ...
GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, ...
Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events, Fierce has learned. | Novartis and Bristol Myers Squibb have halted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results